Market momentum Zealand Pharma has a growing obesity program with high-profile partners such as Roche and Boehringer Ingelheim, presenting opportunities for co-development, licensing discussions, and potential expansion of obesity-focused peptide therapies into adjacent metabolic indications.

US market focus A recent hire to lead US marketing signals intensified focus on the United States, creating openings for direct sales support, regional partnerships, and tailored market access strategies to accelerate adoption of Zealand’s peptide medicines in the key US market.

Oral small molecules The China R&D hub collaboration for oral small-molecule metabolic therapies suggests potential collaborations or regional licensing deals to complement Zealand’s peptide pipeline, expanding beyond injectables into orally administered options.

Funding & growth With substantial overall funding and a multi-program pipeline, there are opportunities to propose strategic collaborations, co-investment in late-stage programs, or advisory roles to unlock faster progression through clinical milestones and market authorization.

ADA and investor visibility Active participation in ADA conferences and investor events indicates an openness to partnerships and equity-raising dialogues; leverage these touchpoints to introduce new partnerships, joint ventures, or research collaborations that align with Zealand’s metabolic disease focus.